| 33.97 0.65 (1.95%) | 05-08 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 41.8 | 1-year : | 48.82 |
| Resists | First : | 35.79 | Second : | 41.8 |
| Pivot price | 33.48  |
|||
| Supports | First : | 32.53  |
Second : | 30.52 |
| MAs | MA(5) : | 33.66 |
MA(20) : | 33.52 |
| MA(100) : | 28.73 |
MA(250) : | 25.66 |
|
| MACD | MACD : | 0.5 |
Signal : | 0.6 |
| %K %D | K(14,3) : | 54.1 |
D(3) : | 52.1 |
| RSI | RSI(14): 56.8 |
|||
| 52-week | High : | 35.79 | Low : | 18.46 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ CLDX ] has closed below upper band by 32.5%. Bollinger Bands are 40% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 34.98 - 35.12 | 35.12 - 35.24 |
| Low: | 32.25 - 32.42 | 32.42 - 32.56 |
| Close: | 33.68 - 33.95 | 33.95 - 34.19 |
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
Fri, 08 May 2026
Weighing Celldex Therapeutics (CLDX) Valuation As Price-To-Book And DCF Send Mixed Signals - simplywall.st
Fri, 08 May 2026
Celldex: Q1 Earnings Snapshot - theheraldreview.com
Thu, 07 May 2026
Celldex Therapeutics (CLDX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Thu, 07 May 2026
Celldex: Q1 Earnings Snapshot - kens5.com
Thu, 07 May 2026
Earnings Flash (CLDX) Celldex Therapeutics, Inc. Reports Q1 Revenue $0.0M, vs. FactSet Est of $795K - marketscreener.com
Thu, 07 May 2026
Celldex (NASDAQ: CLDX) Q1 loss grows while $345M raise funds pipeline - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 78 (M) |
| Held by Insiders | 6.137e+007 (%) |
| Held by Institutions | 0.2 (%) |
| Shares Short | 9,240 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -2.8399e+008 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -72 % |
| Return on Assets (ttm) | 27.2 % |
| Return on Equity (ttm) | -26.2 % |
| Qtrly Rev. Growth | 1.54e+006 % |
| Gross Profit (p.s.) | -74.75 |
| Sales Per Share | -33.85 |
| EBITDA (p.s.) | -2.02942e+008 |
| Qtrly Earnings Growth | -4 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -211 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -1.01 |
| Price to Cash Flow | 5.14 |
| Dividend | 0 |
| Forward Dividend | 8.31e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|